Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Roka Bioscience (ROKA) Share Price
Media coverage about Roka Bioscience (NASDAQ:ROKA) has been trending somewhat positive on Monday, Accern Sentiment reports. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Roka Bioscience earned a media sentiment score of 0.01 on Accern’s scale. Accern also gave media stories about the medical research company an impact score of 45.2136368427551 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Roka Bioscience (ROKA) traded down $0.03 during midday trading on Monday, reaching $0.98. The company had a trading volume of 85,300 shares, compared to its average volume of 373,865. Roka Bioscience has a 1 year low of $0.66 and a 1 year high of $6.20.
In related news, major shareholder Orbimed Advisors Llc sold 127,601 shares of the stock in a transaction dated Wednesday, September 27th. The stock was sold at an average price of $0.98, for a total transaction of $125,048.98. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 803,894 shares of company stock worth $603,915 over the last quarter. 29.20% of the stock is currently owned by company insiders.
Roka Bioscience Company Profile
Roka Bioscience, Inc is a molecular diagnostics company. The Company is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Company offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications.
Receive News & Stock Ratings for Roka Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roka Bioscience Inc. and related stocks with our FREE daily email newsletter.